35 completed, 3 unknown, 2 terminated, 1 not yet recruiting. 13 Phase 3, 9 Phase 1, 9 Phase 2, 6 Phase 4, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 9, Unknown 3, Terminated 1 |
| Phase 1 | 9 | Completed 8, Terminated 1 |
| Phase 2 | 9 | Completed 7, Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 6 | Completed 6 |
| Not applicable | 4 | Completed 4 |
Follow fosamprenavir: new trials by email Literature Review of fosamprenavir trials Research Report on fosamprenavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Fosamprenavir for GERD Fosamprenavir Calcium 700 MG Oral Tablet, Placebo - Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 60 | 2027-10-01 | 2026-09-10 |
| Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction Fosamprenavir Calcium, Placebo - Laryngopharyngeal Reflux | Phase 2 | Recruiting | Medical College of Wisconsin | 104 | 2026-10-01 | 2026-09-10 |
| HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen Dolutegravir, PI, 2 NRTI - HIV-1 | Phase 4 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 44 | 2015-06-01 | 2017-06-14 |
| Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV | Phase 3 | Completed | University Hospital, Tours | 224 | 2014-12-01 | 2025-12-26 |
| MARCH Central Nervous System Substudy Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors, Arm 2 Maraviroc and Protease Inhibitors, Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors - HIV-1 Infection | Completed | Kirby Institute | 28 | 2012-06-01 | 2016-01-20 | |
| MARCH Renal Substudy arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors, Arm 2 boosted protease inhibitors and maraviroc, Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc - Proteinuria, HIV | Phase 4 | Completed | Kirby Institute | 76 | 2012-06-01 | 2016-01-20 |
| Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects Maraviroc, Fosamprenavir/ritonavir, Maraviroc + Fosamprenavir/ritonavir - Healthy | Phase 1 | Completed | ViiV Healthcare | 28 | 2011-04-01 | 2011-06-29 |
| HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir Fosamprenavir - Chronic HIV Infection, HCV Coinfection | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 42 | 2011-03-01 | 2014-05-30 |
| GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir GSK1349572, Fosamprenavir, Ritonavir - Infections, Human Immunodeficiency Virus and Herpesviridae | Phase 1 | Completed | ViiV Healthcare | 27 | 2010-09-01 | 2017-01-19 |
| Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects Maraviroc, Fosamprenavir/ritonavir, Maraviroc + Fosamprenavir/ritonavir - Healthy | Phase 1 | Terminated | ViiV Healthcare | 14 | 2010-07-01 | 2011-02-04 |
| Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA) fosamprenavir/ritonavir, olanzapine - HIV Infections | Phase 1 | Completed | Radboud University Medical Center | 24 | 2009-11-01 | 2020-11-30 |
| Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Lovaza, fosamprenavir/ritonavir - Hypertriglyceridemia, HIV Infection | Phase 4 | Completed | Felizarta, Franco, M.D. | 36 | 2009-09-01 | 2012-04-18 |
| Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir Posaconazole, Fosamprenavir, Ritonavir - HIV Infection, Fungal Infection | Phase 1 | Completed | Radboud University Medical Center | 24 | 2009-01-01 | 2020-11-12 |
| An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects Raltegravir, Fosamprenavir, Ritonavir - Healthy | Not applicable | Completed | Garden State Infectious Disease Associates, PA | 45 | 2008-12-01 | 2016-01-29 |
| An Interaction Study to Assess Drug Levels in Healthy Adult Subjects Maraviroc, Fosamprenavir, Ritonavir - Healthy | Phase 2 | Completed | Garden State Infectious Disease Associates, PA | 45 | 2008-10-01 | 2016-01-29 |
| Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut raltegravir, Study NNRTI, Study PI - HIV Infections | Not applicable | Completed | University of California, San Francisco | 8 | 2008-09-01 | 2012-07-23 |
| A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT Efavirenz 600mg, Boosted Lexiva - Human Immunodeficiency Virus Infections | Phase 3 | Completed | Georgetown University | 101 | 2008-07-01 | 2013-07-02 |
| VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state. Telaprevir; Darunavir; Ritonavir; Fosamprenavir - Hepatitis C, Telaprevir | Phase 1 | Completed | Tibotec BVBA | 40 | 2008-06-01 | 2010-12-17 |
| Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin - Opioid Dependency, HIV Infections | Phase 1 | Completed | University of California, San Francisco | 63 | 2008-04-01 | 2014-05-06 |
| An Interaction Study to Assess Drug Levels in Healthy Adult Subjects Raltegravir, Fosamprenavir, Ritonavir - Healthy | Not applicable | Completed | Garden State Infectious Disease Associates, PA | 44 | 2008-01-01 | 2016-01-29 |
Showing 20 of 42. Sign in to see all of them.
HIV Infections (21) · Acquired Immunodeficiency Syndrome (9) · Infections (9) · AIDS Dementia Complex (1) · Cognitive Dysfunction (1) · Coinfection (1) · Gastroesophageal Reflux (1) · Hepatitis C (1) · Hypertriglyceridemia (1) · Laryngopharyngeal Reflux (1) · Mycoses (1) · Proteinuria (1)
ViiV Healthcare (10) · GlaxoSmithKline (6) · Garden State Infectious Disease Associates, PA (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Glaxo Wellcome (2) · Kirby Institute (2) · Medical College of Wisconsin (2) · Radboud University Medical Center (2) · University of California, San Francisco (2) · Felizarta, Franco, M.D. (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Fundacion SEIMC-GESIDA (1) · Georgetown University (1) · Germans Trias i Pujol Hospital (1) · Hospital Universitari Vall d'Hebron Research Institute (1)
United States (26) · Spain (9) · France (7) · United Kingdom (6) · Belgium (5) · Canada (5) · Italy (5) · Puerto Rico (5) · Argentina (4) · Germany (4) · Portugal (4) · Romania (4) · Netherlands (3) · Russia (3) · South Africa (3)
David V Condoluci, DO (3) · Alan Winston, MD (1) · Ann C. Collier, MD (1) · Bonaventura Clotet, MD, PhD (1) · David Burger, PharmD, PhD (1) · David M Burger, PharmD PhD (1) · Diane Havlir, MD (1) · Douglas Richman, MD (1) · Elinore F McCance-Katz, M.D., Ph.D. (1) · Franco Felizarta, MD (1)
PMID 15668539, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18383194, PMID 18795962, PMID 18989231, PMID 19420019, PMID 20002783, PMID 20133266, PMID 20632458, PMID 20667889, PMID 20827162, PMID 20939732, PMID 21126954, PMID 21283017, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 23494984, PMID 23741991, PMID 23811744, PMID 24352352, PMID 24929949, PMID 25155604, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30715324, PMID 31350995, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33318014, PMID 34076612, PMID 34732682, PMID 40741959
2004 (1), 2005 (1), R01MH058076 (1)